Tocilizumab (Actemra, RoActemra)
Immunotherapy · Approved since 2010
Off-label
med_ema_approved
med_spain_hospital_use med_crc_off_label
IV, Subcutaneous
3 Clinical Trials
Description
Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor and is primarily used in colorectal cancer for managing immune-related adverse events rather than direct anti-tumor therapy. In the CRC setting, it serves as a therapeutic intervention for checkpoint inhibitor-induced colitis and other inflammatory complications that can arise during immunotherapy treatment. This IL-6 receptor antagonist helps control severe inflammatory responses while allowing patients to continue or resume their primary cancer treatment regimen.
Mechanism of Action
Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors, blocking IL-6-mediated signaling pathways that drive inflammatory responses. By inhibiting IL-6 signaling, it reduces the production of inflammatory cytokines and helps resolve immune-mediated tissue damage, particularly in the gastrointestinal tract during checkpoint inhibitor-induced colitis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Actemra, RoActemra |
| Category | Immunotherapy |
| Status | Off-label |
| Estado EMA | med_ema_approved |
| Acceso España | med_spain_hospital_use med_crc_off_label |
| Administration | IV, Subcutaneous |
| Year Approved | 2010 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.